European Leukemia Trial Registry
Trial: AMLSG 09-09

More Details
Title Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation
Scientific Title Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation
Short Title AMLSG 09-09
Trialgroup AMLSG Ulm
Type of Trial multicentric, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status No longer recruiting
Start of Recruitment 02.12.2009
Leader Döhner, Prof. Dr. med., Hartmut
Contactperson

Study Centre
Weber, Daniela
Tel: +49 (0)731 50056072
Fax: +49 (0)731 50045905
Email: aml.sekretariat@uniklinik-ulm.de

Centre of Trial Universitätsklinikum Ulm
Shortprotocol Shortprotocol
created 05.11.2009 Roswitha Kotthoff
changed 09.04.2018 Martina Wolkenfeld
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org